ArticleCureus2026
Serum Magnesium Levels Across Clinical Stages of Alcoholic Liver Disease: A Cross-Sectional Study From South India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAlcoholic liver disease (ALD) involves progressive hepatic dysfunction and frequent electrolyte disturbances, but the relationship between serum magnesium and clinically staged ALD remains unclear. This study aimed to explore the relationship between the two with established markers of disease severity. MATERIALS AND
methodsIn this hospital‑based cross‑sectional study, 80 adults with confirmed ALD were enrolled at a tertiary center in Karaikal, TN, IND, between January and December 2025. Patients were classified as non‑cirrhotic ALD, compensated cirrhosis, or decompensated cirrhosis. Clinical evaluation, laboratory tests (including serum magnesium), viral serology, ultrasonography, and the model for end-stage liver disease (MELD) and Maddrey's discriminant function (DF) scores were obtained. Prognostic assessment was performed using the MELD, Maddrey's DF, and the age-bilirubin-INR-creatinine (ABIC) scores.
resultsMost patients had non‑cirrhotic ALD (53.8%) or decompensated cirrhosis (40.0%); nearly all were male. With advancing stages, hemoglobin, platelets, sodium, albumin, and coagulation indices worsened, and MELD and DF scores increased significantly. Serum magnesium showed a progressive, borderline non‑significant decline (p=0.071).
conclusionConventional biochemical markers and prognostic scores robustly reflected ALD severity, while serum magnesium trended downward across stages, suggesting a potential adjunctive role rather than a standalone severity marker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.